Physician profile
Afaque Akhtar
NPI 1053309419
$1,875.17
in general payments reported to CMS, 2019-2025
26 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $60.72 · 2021: $168 · 2022: $205 · 2023: $115 · 2024: $894 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $610 · Food and Beverage: $589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $609.70 |
| Food and Beverage | $589.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $710.32 | 2021-2024 | Venaseal, Activos 10 Bone Cement |
| Novo Nordisk INC | $195.75 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $105.88 | 2019-2021 | |
| Abbvie INC. | $104.00 | 2020-2025 | |
| Amgen INC. | $102.00 | 2019-2025 | Otezla, Repatha, Repatha |
| Orexo US, INC. | $101.63 | 2023-2025 | Zubsolv |
| Lilly USA, LLC | $100.72 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $62.89 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $45.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $43.75 | 2020-2022 | |
| Amarin Pharma, INC. | $41.99 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $35.31 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $27.20 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $24.30 | 2024 | Imcivree |
| Indivior INC. | $19.15 | 2025 | Sublocade |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $17.35 | 2024 | Hyalgan, Hymovis, Triluron |
| Viatris Specialty LLC | $16.99 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $16.89 | 2023 | Xarelto |
| Exact Sciences Corporation | $15.63 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.60 | 2022 | |
| Depuy Synthes Sales INC. | $13.35 | 2024 | Orthovisc |
| Sanofi-Aventis U.S. LLC | $12.61 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.46 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $12.35 | 2021 | |
| Mylan Specialty L.P. | $11.93 | 2019 | |
| Medtronic Vascular, INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afaque Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.